AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

February 6, 2020 GMT

NORFOLK, Va.--(BUSINESS WIRE)--Feb 6, 2020--

ReAlta Life Sciences, Inc., today announced that U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PIC1-dPEG24 for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates.

“There is an urgent need for new therapeutic options to treat hypoxic-ischemic encephalopathy, a devastating condition that profoundly impacts newborns and their families,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s chief executive officer. “ReAlta is passionate about supporting this vulnerable population and bringing forward the first pharmacological therapy for the treatment of HIE. The orphan drug designation for our RLS-0071 compound is an important milestone in ReAlta’s strategic plan to advance our PIC1 platform to address life-threatening medical needs.”

The FDA’s Office of Orphan Drug Products grants orphan status to drugs intended to treat rare disorders that affect fewer than 200,000 people in the U.S. The designation provides certain benefits to the drug developer, including seven years of market exclusivity upon FDA approval, prescription drug user fee waivers and tax credits for qualified clinical trials.

ReAlta intends to submit an Investigational New Drug (IND) application to FDA for HIE later this year, begin first-in-man clinical studies in late 2020, and then begin HIE Phase 2 studies in neonates in 2021.

About Hypoxic-Ischemic Encephalopathy (HIE)

Hypoxic Ischemic Encephalopathy (HIE) is also known as neonatal brain asphyxia or ‘blue baby’. In this disease, otherwise normal healthy infants suffer from oxygen starvation to the brain. This can be caused by several processes, including placental tear or tight cord around the neck. These infants are typically otherwise healthy, and the event is abrupt and unanticipated. Approximately 6,500 to 12,000 newborns in the U.S. are affected every year, or about one every hour. Many of these infants will die after birth or suffer permanent, life-long brain damage, such as severe mental retardation, or cerebral palsy, or both. HIE is frequently emotionally and financially devastating for the families of HIE babies. Worldwide, HIE is among the top three causes of infant death. The current state-of-the-art treatment for HIE is therapeutic hypothermia; there are currently no pharmacological therapies approved for HIE.

About ReAlta Life Sciences

ReAlta Life Sciences, Inc. is an early-stage biotech company dedicated to harnessing the power of the immune system to address life-threatening medical needs. To support its vision, ReAlta has developed a novel class of drugs with unique multi-modal therapeutic capabilities that rebalance complement and inflammatory processes. The company was incorporated in late 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200206005139/en/

Ulrich Thienel, MD, PhD atinfo@realtalifesciences.comor (757) 901-0460

KEYWORD: UNITED STATES NORTH AMERICA VIRGINIA

INDUSTRY KEYWORD: RESEARCH FAMILY PHARMACEUTICAL CONSUMER HOSPITALS PARENTING CLINICAL TRIALS SCIENCE BABY/MATERNITY BIOTECHNOLOGY WOMEN FDA HEALTH

SOURCE: ReAlta Life Sciences, Inc.

Copyright Business Wire 2020.

PUB: 02/06/2020 09:30 AM/DISC: 02/06/2020 09:30 AM

http://www.businesswire.com/news/home/20200206005139/en